ATO

DRUG2 trials

Sponsors

South China Children's Leukemia Group, First Affiliated Hospital Xi'an Jiaotong University

Conditions

APLChildhood Acute Promyelocytic Leukemia

Phase 3

Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).

RecruitingNCT07503730

First Affiliated Hospital Xi'an Jiaotong UniversityAPL

Start: 2025-06-01End: 2028-06-01Target: 224Updated: 2026-03-31

Phase 4

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

CompletedNCT02200978

South China Children's Leukemia GroupChildhood Acute Promyelocytic Leukemia

Start: 2011-09-30End: 2021-10-31Updated: 2022-05-10

Related Papers

Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group

Therapeutic Advances in Hematology2025-01-013 citations

Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial

Evidence-based Complementary and Alternative Medicine2022-07-056 citations

The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.

2022-06-279 citations